0002019875-26-000004.txt : 20261104 0002019875-26-000004.hdr.sgml : 20261104 20261104172649 ACCESSION NUMBER: 0002019875-26-000004 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20261104 DATE AS OF CHANGE: 20261104 EFFECTIVENESS DATE: 20261104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AI3 Bio, Inc. CENTRAL INDEX KEY: 0002019875 ORGANIZATION NAME: EIN: 843148800 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-603657 FILM NUMBER: 261523827 BUSINESS ADDRESS: STREET 1: 99 COOLIDGE AVE, SUITE 201 CITY: WATERTOWN STATE: MA BUSINESS PHONE: 617-701-7014 MAIL ADDRESS: STREET 1: 99 COOLIDGE AVE, SUITE 201 CITY: WATERTOWN STATE: MA FORMER COMPANY: FORMER CONFORMED NAME: Corner Therapeutics, Inc. DATE OF NAME CHANGE: 20240415 D 1 primary_doc.xml X0708 D LIVE 0002019875 AI3 Bio, Inc. 99 COOLIDGE AVE, SUITE 201 WATERTOWN MA MASSACHUSETTS 02472 617-701-7014 DELAWARE Corner Therapeutics, Inc. Corporation true Steven Altschuler 99 Coolidge Ave, Suite 201 Watertown WA WASHINGTON 02472 Executive Officer Director Michael Lyman 99 Coolidge Ave, Suite 201 Watertown MA MASSACHUSETTS 02472 Executive Officer Nick Seaver 99 Coolidge Ave, Suite 201 Watertown MA MASSACHUSETTS 02472 Executive Officer Director Fabian Tenenbaum 99 Coolidge Ave, Suite 201 Watertown MA MASSACHUSETTS 02472 Director Jeanne Cunicelli 99 Coolidge Ave, Suite 201 Watertown MA MASSACHUSETTS 02472 Director Alan Ezekowitz 99 Coolidge Ave, Suite 201 Watertown MA MASSACHUSETTS 02472 Director Jonathan Kagan 99 Coolidge Ave, Suite 201 Watertown MA MASSACHUSETTS 02472 Executive Officer Biotechnology Decline to Disclose 06b false 2026-06-09 false true true Pursuant to an Agreement and Plan of Merger dated as of June 9, 2026 (the "Merger Agreement"), all shares of capital stock of Novasenta, Inc. held by accredited investors were exchanged for shares of the Issuer. 0 Indefinite 0 Indefinite Shares of capital stock of Novasenta, Inc. were exchanged for shares of capital stock of the Issuer based on an exchange ratio determined pursuant to the terms of the Merger Agreement. false 7 0 0 0 false AI3 Bio, Inc. /s/ Steven Altschuler Steven Altschuler Chief Executive Officer 2026-11-04